Glenmark Pharma Q2 FY26 Analysis: One-Time Gain Masks Core Operational Headwinds

Glenmark Pharmaceuticals Ltd. reported Q2 FY26 headline figures skewed by a significant one-time income Reported revenue saw a 76% YoY surge to ₹6,047 crore, driven by a ₹3,670 crore exceptional payment from the AbbVie licensing agreement. Consequently, reported Net Profit stood at ₹610 crore. Adjusting for the one-time income, core revenue stood at ₹2,380 crore, marking a steep 30.8% YoY decline. The company reported an operational loss of ₹870 crore and an adjusted net loss of ₹900 crore for the quarter. The primary driver of this loss was a temporary but severe disruption in the India formulations business, which de-grew 87.1% YoY to ₹160 crore. Management attributes this collapse to a major GST 2.0 framework transition, which led to: Significant distributor inventory reductions. Postponement of orders. Increased freight and reverse logistics costs. Management noted this was a one-time correction, highlighting that secondary sales (sell-through) remained strong, growing 10.8% YoY and outperforming the Indian Pharmaceutical Market (IPM). Exceptional Items The P&L was further impacted by exceptional items (beyond the AbbVie income), including: A ₹590 crore provision on certain inventories post-GST 2.0. A ₹490 crore impact from changes in inventory models and receivables. A ₹200 crore impairment. International Business Performance International markets provided stability: North America: Grew 7.4% YoY to ₹800 crore, led by injectables. Europe: Grew 8.5% YoY to ₹750 crore. Emerging Markets: Declined 6.5% YoY to ₹650 crore. Management Commentary & Outlook Management stressed that the AbbVie partnership validates the company's R&D capabilities and supports a self-sustaining innovation model. The company expects the India business performance to normalize from Q3 FY26 onwards as the GST-related adjustments subside.